Forward-Looking Statements
Certain statements, apart from purely historic data, together with estimates, projections, statements referring to our enterprise plans, targets, and anticipated working outcomes, and the assumptions upon which these statements are based mostly, are "forward-looking statements" inside the which means of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements usually are recognized by the phrases "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and related expressions. We intend such forward-looking statements to be coated by the safe-harbor provisions for forward-looking statements contained within the Private Securities Litigation Reform Act of 1995, and are together with this assertion for functions of complying with these safe-harbor provisions. Forward-looking statements are based mostly on present expectations and assumptions which are topic to dangers and uncertainties which can trigger precise outcomes to vary materially from the forward-looking statements. Our skill to predict outcomes or the precise impact of future plans or methods is inherently unsure. Factors which may have a cloth adversarial impact on our operations and future prospects on a consolidated foundation embrace, however aren't restricted to: modifications in financial circumstances, legislative/regulatory modifications, availability of capital, rates of interest, competitors, cybersecurity, and usually accepted accounting ideas. These dangers and uncertainties must also be thought of in evaluating forward-looking statements and undue reliance shouldn't be positioned on such statements. We undertake no obligation to replace or revise publicly any forward-looking statements, whether or not in consequence of new data, future occasions or in any other case. Further, data regarding our enterprise, together with extra elements that would materially have an effect on our monetary outcomes, is included herein and in our different filings with theSEC . Overview Since the acquisition ofGlobal Stem Cell Group in August final yr, our focus has been primarily devoted to its operations serving the markets within the regenerative drugs trade. We nonetheless have numismatics operation, however the total plan for the corporate is simply too transfer from the sale of cash, paper foreign money, bullion and medals into what we imagine is a extra profitable alternative for
our
firm.
We work with medical doctors and their employees to supply merchandise, options, tools,
companies, and coaching to assist them achieve success within the software of Stem
Cell Therapies. Our group combines options from intensive scientific analysis
with the manufacturing and commercialization of viable cell remedy and immune
assist associated merchandise that we imagine will change the course of conventional
drugs all over the world endlessly. Our technique permits us the power to create
quick income streams by means of product gross sales, distribution, and scientific
functions, pushed by our intensive schooling platform. Our income comes
instantly from the coaching and the seminars, from the resale of these kits,
merchandise, and tools, companies, and from the reoccurring software of our
course of utilizing the kits and options we offer.
Page 29 of 42
Global Stem Cells Group is a pacesetter within the Stem Cell and Regenerative Medicine
fields, protecting scientific analysis, affected person functions, together with doctor
coaching by means of our state-of-the-art international community of corporations. The Company's
mission is to allow physicians to make the advantages of stem cell drugs a
actuality for sufferers all over the world. They have been educating medical doctors on the
science and software of cell-based therapeutics for the previous 10 years. Our
skilled trademarked affiliation "ISCCA" INTERNATIONAL SOCIETY FOR STEM CELL
APPLICATION is a worldwide community of medical professionals that leverages these
multinational relationships to construct greatest practices and additional our mission.
The Company envisions the power to enhance “health-span” by means of the invention
and developments of new mobile remedy merchandise, and cutting-edge expertise.
affected by the covid 19 pandemic. As we glance to get well in 2022, we’re
integrating each side of the regenerative drugs trade. During 2022, we
plan so as to add manufacturing and commercialization of viable cell remedy and
immune assist associated merchandise that we imagine will change the course of
conventional drugs all over the world endlessly.
We imagine this technique will enable us the power to extend our present
revenues and create quick income streams by means of product gross sales,
distribution, and scientific functions, pushed by our intensive schooling
platform listed below are our foremost tasks and income turbines for 2022 and past.
Results of Operations
Results of Operations for the Three Months Ended
Below is a abstract of the outcomes of operations for the three months ended
For the Three Months Ended September 30,
2022 2021 $ Change % Change
Revenue $ 374,359 $ 165,042 $ 209,317 126.83 %
Cost of income 109,364 88,520 20,844 23.55 %
Gross revenue 264,995 76,522 188,473 246.30 %
Operating bills
Advertising and advertising and marketing 80,931 22,351 58,580 262.09 %
Professional charges 143,118 336,299 (193,181 ) -57.44 %
Officer compensation 22,500 518,833 (496,333 ) -95.66 %
Depreciation and
amortization expense 39,882 12,947 26,935 208.04 %
Investor relations 32,749 32,574 175 0.54 %
General and administrative-
associated celebration - 8,116,269 (8,116,269 ) -100 %
General and administrative 107,908 52,651 55,257 104.95 %
Total working bills 427,088 9,091,924
(8,664,836 ) -95.30 %
Other revenue (expense) Interest expense (1,183,166 ) (900,039 ) (283,127 ) 31.46 % Derivative monetary devices 876 - 876 00 % Net loss$ (1,344,383 ) $ (9,915,441 ) $ 8,571,058 -86.44 % Page 30 of 42 Revenue
Revenue elevated by 126.83% within the quantity of$209,317 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021. The key motive for the rise in income was a outcome of the acquisition ofGlobal Stem Cells Group, Inc. onAugust 18, 2021 . Revenue from viable cell remedy and immune assist associated merchandise together with doctor coaching elevated by$214,114 offset by a lower in sale of cash, metals and paper cash of$4,797 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021.
Listed beneath are the revenues, price of revenues and gross income by Company for
the three months ended
For the Three Months Ended
September 30, 2022
Global Stem Meso
Cells Group Numismatics Total
Revenue $ 367,697 $ 6,662 $ 374,359
Cost of income 102,779 6,585 109,364
Gross revenue $ 264,918 $ 77 $ 264,995
Gross revenue % 72.05 % 1.16 % 70.79 %
We anticipate to extend our revenues in future quarters from our operations
related to Global Stem Cells with much less anticipated revenues in future quarters
related to our numismatic operations.
Operating bills Operating bills decreased by 95% within the quantity of$8,664,836 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021. Listed beneath are the key modifications to working bills: Advertising and advertising and marketing charges elevated by$58,580 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily because of the acquisition ofGlobal Stem Cells Group, Inc. onAugust 18, 2021 . Professional charges decreased by$193,181 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily on account of audit and accounting bills because of the acquisition ofGlobal Stem Cells Group, Inc. on August
18, 2021. Officer compensation decreased by$496,333 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily because of the issuance of 896 shares of Series DD Preferred Stock of the Company toDave Christensen , present Director, President, Chief Executive Officer, Chief Financial Officer and Secretary as compensation pursuant to theProfessional Service Consulting Agreement. The$503,072 worth of the 896 shares of Series DD Convertible Preferred Stock is predicated on changing right into a quantity of totally paid and nonassessable shares of frequent inventory decided by multiplying the quantity of issued and excellent shares of frequent inventory of the Company on the date of conversion by 3.17 conversion worth. Page 31 of 42
Depreciation and amortization elevated by
completion of
General and administrative-related celebration expense lower by$8,116,269 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily because of the issuance of the 1,000 shares of the Company's Series CC Convertible Preferred Stock toLans Holdings Inc. terminated and changed with a money fee as consideration. The Company paidLans Holdings Inc. , by supply in escrow, an quantity equal to$8,200,000 , offset by$83,731 the worth of the 1,000 shares of the Company's Series CC Convertible Preferred Stock terminated.
General and administrative expense improve by
ended
the acquisition of
Other expense Other expense elevated by$282,251 for the three months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily in consequence of the rise in curiosity on promissory notes. During the 9 months endedSeptember 30, 2021 , we acquired$11,400,000 in proceeds acquired from the issuance of promissory notes. We anticipate different expense to extend in future quarters as a outcome of the curiosity on the brand new debt. Net Loss
We recorded a internet loss of
2022
Results of Operations for the Nine Months Ended
Below is a abstract of the outcomes of operations for the 9 months ended
For the Nine Months Ended September 30,
2022 2021 $ Change % Change
Revenue $ 988,958 $ 185,254 $ 803,704 433.84 %
Cost of income 468,838 115,170 353,668 307.08 %
Gross revenue 520,120 70,084 450,036 642.14 %
Operating bills
Advertising and advertising and marketing 216,506 22,732
193,774 852.43 % Professional charges 735,186 665,544 69,642 10.46 % Officer compensation 67,500 552,932 (485,432 ) -87.79 % Depreciation and amortization expense 102,184 13,347 88,837 665,59 % Investor relations 127,633 53,046 74,587 140.61 %
General and administrative- associated celebration - 8,116,269 (8,116,269 ) -100.00 % General and administrative 341,131 69,206 271,925 392.92 % Total working bills 1,590,140 9,493,076
(7,902,936 ) -83.25 %
Other revenue (expense) Interest expense (3,454,874 ) (1,659,724 ) 1,795,150 108.16 % Derivative monetary devices 10,482 - 10,482 0.00 % Other expense - (231,109 ) 231,109 -100.00 % Net loss$ (4,514,412 ) $ (11,313,825 ) $ 6,799,413 -60.10 % Page 32 of 42 Revenue
Revenue elevated by 433.84% within the quantity of$803,704 for the 9 months endedSeptember 30, 2022 , in comparison with the identical interval in 2021. The key motive for the improve in income was a outcome of the acquisition ofGlobal Stem Cells Group, Inc. onAugust 18, 2021 . Revenue from viable cell remedy and immune assist associated merchandise together with doctor coaching elevated by$810,384 offset by a lower in sale of cash, metals and paper cash of$6,680 for the 9 months endedSeptember 30, 2022 , in comparison with the identical interval in 2021.
Listed beneath are the revenues, price of revenues and gross income by Company for
the 9 months ended
For the Nine Months Ended
September 30, 2022
Global Stem Meso
Cells Group Numismatics Total
Revenue $ 963,967 $ 24,991 $ 988,958
Cost of income 445,814 23,024 468,838
Gross revenue $ 518,153 $ 1,967 $ 520,120
Gross revenue % 53.75 % 7.87 % 52.59 %
We anticipate to extend our revenues in future quarters from our operations
related to Global Stem Cells with much less anticipated revenues in future quarters
related to our numismatic operations.
Operating bills
Operating bills decreased by 83.25% within the quantity of$7,902,936 for the 9 months endedSeptember 30, 2022 , in comparison with the identical interval in 2021. Listed beneath are the key modifications to working bills: Advertising and advertising and marketing charges elevated by$193,774 for the 9 months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily because of the acquisition ofGlobal Stem Cells Group, Inc. onAugust 18, 2021 . Professional charges elevated by$69,642 for the 9 months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily on account of audit and accounting bills. Officer compensation decreased by$485,432 for the 9 months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily because of the issuance of 896 shares of Series DD Preferred Stock of the Company toDave Christensen , present Director, President, Chief Executive Officer, Chief Financial Officer and Secretary as compensation pursuant to theProfessional Service Consulting Agreement. The$503,072 worth of the 896 shares of Series DD Convertible Preferred Stock is predicated on changing right into a quantity of totally paid and nonassessable shares of frequent inventory decided by multiplying the quantity of issued and excellent shares of frequent inventory of the Company on the date of conversion by 3.17 conversion worth.
Depreciation and amortization elevated by
completion of
General and administrative-related celebration expense lower by$8,116,269 for the 9 months endedSeptember 30, 2022 , in comparison with the identical interval in 2021, primarily because of the issuance of the 1,000 shares of the Company's Series CC Convertible Preferred Stock toLans Holdings Inc. terminated and changed with a money fee as consideration. The Company shall payLans Holdings Inc. , by supply in escrow, an quantity equal to$8,200,000 , offset by$83,731 the worth of the 1,000 shares of the Company's Series CC Convertible Preferred Stock terminated.
General and administrative expense improve by
ended
the acquisition of
Page 33 of 42
Other expense
Other expense elevated by $1,553,559 for the 9 months ended September 30,
2022 , in comparison with the identical interval in 2021, primarily in consequence of the rise
in curiosity on promissory notes. During the 9 months ended September 30,
2021 , we acquired $11,400,000 in proceeds acquired from the issuance of
promissory notes. We anticipate different expense to extend in future quarters as a
outcome of the curiosity on the brand new debt.
Net Loss
We recorded a internet loss of
2022
Liquidity and Capital Resources
Since inception, the Company has financed its operations by means of personal
placements and convertible notes. The following is a abstract of the money and
money equivalents as of
September 30, December 31, $ %
2022 2021 Change Change
Cash and money equivalents $ 1,769,636 $ 2,978,525 $ (1,208,889 ) -40.59 %
© Edgar Online, supply
